加载中
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
前收盘价
US$0.718
−US$0.082 · -10.25%
盘中时间采用ET。市场数据可能有所延迟。
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
日内区间
当前US$0.718
52周区间
当前US$0.718
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
46
合理估值
情绪
55
多空交织
风险
73
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company’s pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto’s thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
日内区间
当前US$0.718
52周区间
当前US$0.718
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 505.4万 USD | 337.8万 USD | 9万 USD | 11.1万 USD | 28.3万 USD |
| 销售、一般及管理费用 | 3170.3万 USD | 1204.1万 USD | 517.2万 USD | 304.9万 USD | 289万 USD |
| 营业费用 | 3675.7万 USD | 1541.9万 USD | 526.2万 USD | 316万 USD | 317.3万 USD |
| 利息收入 | 2.8万 USD | 1.3万 USD | 1.5万 USD | 197.6万 USD | — |
| 利息支出 | 31.9万 USD | 150.6万 USD | 21.1万 USD | — | — |
| 折旧和摊销 | 242.5万 USD | 45.7万 USD | — | — | — |
| 营业利润 | −3675.7万 USD | −1541.9万 USD | −526.2万 USD | −316万 USD | −317.3万 USD |
| 净利润 | −3922.4万 USD | −1780.2万 USD | −53.5万 USD | −488.7万 USD | −365.7万 USD |
公司数据更新于 2026年10月11日。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
